Recent News

• 04.22.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 04.22.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 04.22.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 03.19.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 03.19.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 03.19.2025 - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
• 03.12.2025 - Ultragenyx anuncia la aprobación de Evkeeza® (evinacumab) por parte de la COFEPRIS para el tratamiento de la Hipercolesterolemia Familiar Homocigota (HoFH)
• 03.12.2025 - Leerink Partners Global Biopharma Conference
• 03.12.2025 - Leerink Partners Global Biopharma Conference
• 03.11.2025 - Barclays 27th Annual Global Healthcare Conference

Recent Filings

• 03.28.2025 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 03.28.2025 - ARS Annual Report to Security Holders
• 03.28.2025 - DEF 14A Other definitive proxy statements
• 03.10.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities
• 03.04.2025 - 4 Statement of changes in beneficial ownership of securities